Table 3.
Percentage Prevalence of Pretherapy Drug Resistance Stratified by Year
| Year | No resistance (n)a | Yes resistance (n)b | Pretherapy resistance (%) |
|---|---|---|---|
| AMU Kampala | |||
| 2002 (n=17) | 15 | 2 | 11.8 |
| 2003 (n=51) | 48 | 3 | 5.9 |
| 2004 (n=12) | 12 | 0 | 0.0 |
| AMU total (n=80) | 75 | 5 | 6.3 |
| MBA Mbarara | |||
| 2005 (n=61) | 60 | 1 | 1.6 |
| 2006 (n=124) | 122 | 2 | 1.6 |
| 2007 (n=168) | 162 | 6 | 3.6 |
| 2008 (n=93) | 90 | 3 | 3.2 |
| 2009 (n=36) | 36 | 0 | 0.0 |
| 2010 (n=6) | 6 | 0 | 0.0 |
| MBA total (n=488) | 476 | 12 | 2.5 |
a
This table includes two individuals who were unenrolled later due to suspected prior antiretroviral use or for reasons other than not being antiretroviralnaive; pretherapy resistance was not detected in either subject.
b
Patients with pretherapy plasma drug concentrations detected by HPLC-MS/MS were excluded for a closer estimate of the prevalence of transmitted drug resistance.